Marvin Allen
Cardiovascular Disease · Provo, UTNPI 1831154566
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (51.2%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Lantheus Medical Imaging, Inc. accounts for 76.8% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2020 at $4,713 and has fallen 99.5% since, to $23 in 2024.
Across 167 payments — averaging $52.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lantheus Medical Imaging, Inc.$7K
- Johnson & Johnson$491
- Pfizer$361
- Boston Scientific$243
- Boehringer Ingelheim$232
- Amgen$172
- plus $538 from 10 others
What the payments were for
- Speaking & faculty fees$4,50051%
- Travel & lodging$1,40916%
- Food & beverage$2,87733%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lantheus Medical Imaging, Inc. | 32 | $6,749 |
| Johnson & Johnson | 30 | $491 |
| Pfizer | 31 | $361 |
| Boston Scientific | 18 | $243 |
| Boehringer Ingelheim | 14 | $232 |
| Amgen | 9 | $172 |
| Actelion Pharmaceuticals US, Inc. | 12 | $171 |
| AstraZeneca | 7 | $87 |
| Abbott | 3 | $62 |
| Novartis | 3 | $46 |
| Nevro Corp. | 1 | $42 |
| E.r. Squibb & Sons, L.L.C. | 2 | $37 |
| Amarin Pharma, Inc. | 2 | $33 |
| AbbVie | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Amryt Pharma Holdings Ltd | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Definity$6,169
How this compares
$8,786 in reported general payments places this provider in the 75th percentile of 131 cardiovascular disease providers in Utah.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 62 | $43,535 |
| Atorvastatin Calcium | 54 | $596 |
| Metoprolol Succinate | 35 | $421 |
| Carvedilol | 23 | $421 |
| Losartan Potassium | 36 | $418 |
| Nebivolol Hcl | 13 | $356 |
| Potassium Chloride | 12 | $305 |
| Lisinopril | 27 | $288 |
| Rosuvastatin Calcium | 18 | $243 |
| ClopidogrelClopidogrel Bisulfate | 18 | $213 |
| Amlodipine Besylate | 25 | $173 |
| Omeprazole | 17 | $171 |
| Spironolactone | 12 | $129 |
| Metoprolol Tartrate | 11 | $104 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $361 | $43,53562 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 131 cardiovascular disease providers in Utah.
Other cardiovascular disease in Provo
- Stephen WilkinsonProvo$8K
- David PerryProvo$8K
- Phanindra AntharamProvo$6K
- Hussein DaoudProvo$3K
- John RyanSalt Lake City$1.4M
- Robert FowlesSalt Lake City$611K
- Brian WhisenantMurray$416K
- Andrew BehuninDraper$192K
- Jeffrey OsbornSalt Lake City$69K
- James FangSalt Lake City$67K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.